Company News »

INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Ambit Biosciences Corporation Concerning the Fairness of the Sale of the Company to Daiichi Sankyo Company, Ltd.

Business Wire
Share on StockTwits
Published on

Levi & Korsinsky is investigating the Board of Directors of Ambit Biosciences Corporation (“Ambit” or “the Company”) (NasdaqGM: AMBI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Daiichi Sankyo Company, Ltd.

Click here to learn more about the investigation: http://zlk.9nl.com/ambit-biosciences-ambi.

Under the terms of the transaction, Ambit shareholders will receive $15.00 in cash for each share of Ambit stock they own. The investigation concerns whether the Board of Ambit breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Daiichi Sankyo Company, Ltd. is underpaying for Ambit shares.

If you own Ambit common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ambit-biosciences-ambi.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Share on StockTwits

What others are reading on Finances

Sorry. No data so far.


Iron FX 1.11156/1.11128 2.8
XM Markets 1.09948/1.09928 2
FxPro 1.10184/1.10171 1.3
FXCM 1.13943/1.13912 3.1